Stockreport

JPMorgan Upgrades Recursion Pharmaceuticals, Inc. (RXRX) on FAP Treatment Prospects [Yahoo! Finance]

Recursion Pharmaceuticals, Inc. - Class A  (RXRX) 
PDF Recursion Pharmaceuticals (NASDAQ:RXRX) to an Overweight from Neutral and raised the price target to $11 from $10. The upgrade follows promising clinical trials evalua [Read more]